For the latest COVID-19 campus news and resources, visit umassmed.edu/coronavirus.

Buscar Close Search

Print

Nanobody treatment developed by MassBiologics shows promise for treating SARS-CoV-2 infection

Monoclonal antibody derived from IIama protein fragments offers a potentially low-cost and inhalable therapeutic against COVID

By Jim Fessenden

UMass Chan Medical School Communications

noviembre 30, 2022
Yang Wang, MD, PhD

A nanobody—an alternative class of antibody derived from alpaca or IIama protein fragments—developed by MassBiologics of UMass Chan Medical School, blocks SARS-CoV-2 infection in animal models and may be a new therapeutic in the growing number of biologics being explored to treat emerging COVID variants. As published in Frontiers in Immunology, a nasally delivered nanobody could be a noninvasive, low-cost and effective prophylaxis and post-exposure treatment for SARS-CoV-2 and other respiratory pathogens.

A division of UMass Chan, MassBiologics is the only nonprofit, FDA-licensed manufacturer of vaccines in the United States and is a pioneer in the development of human monoclonal antibody treatments for diseases important to public health. A 2020 study by MassBiologics was the first to show that an IgA antibody could successfully block SARS-Cov-2 infection. Nature Communications recently selected this work as one of the most impactful and innovative studies published in the journal since the COVID-19 pandemic

“There is still a great need for therapeutics to counter emerging SARS-CoV-2 variants that cause COVID, particularly for resource-constrained populations,” said principal investigator Yang Wang, MD, PhD, professor of medicine and deputy director of product discovery at MassBiologics. “The challenge for antibody treatments for COVID, however, is that they have been very expensive to deliver because they have to be produced in mammalian cells and they take trained health professionals to administer intravenously. Even the mRNA vaccines require special storage and handling. Our nanobodies, in contrast, can be produced inexpensively in yeast cells and can be delivered simply in a nasal spray.”

The MassBiologics nanobody, designated VHH-IgA, is a fusion of an antigen-binding fragment of the COVID spike protein and a human IgA antibody. When delivered nasally to animal models that had been previously exposed to the SARS-CoV-2 virus, the VHH-IgA effectively bonded to the SARS-CoV-2 spike protein, thereby inhibiting infection. These animals showed a marked reduction in viral loads. Conversely, when treated prophylactically, animal models that were subsequently exposed to the SARS-CoV-2 virus showed lower levels of viral penetration, making the treatment potentially protective against COVID-19.

The VHH-IgA antibody treatment was equally effective against most variants of SARS-CoV-2, including the newer omicron variants. This suggests that a nanobody treatment may also be effective against emerging variants of concern.

“While the current mRNA vaccines and other monoclonal antibody treatments have been effective in curtailing COVID infection, there are multiple reasons why these options might not be readily available to all patients,” said Dr. Wang. “It’s necessary to have other options available, and our VHH-IgA molecule shows great promise as a complementary therapeutic that can neutralize existing infections and preventing new infections.”

The work is a joint effort by investigators at MassBiologics and UMass Chan including Wang, Lisa Cavacini, PhD, professor of medicine and senior director for product discovery at MassBiologics; Katherine A. Fitzgerald, PhD, the Worcester Foundation for Biomedical Research Chair III, professor of medicine, vice chair of research in the Department of Medicine and director of the Program in Innate Immunity; and Celia A. Schiffer, PhD, the Arthur F. and Helen P. Koskinas Professor of Biochemistry and Molecular Biotechnology, and chair and professor of biochemistry & molecular biotechnology. The next step for the team is to perform pre-clinical studies of the VHH-IgA biologic along with toxicology studies before embarking on clinical trials.

“Ultimately, our hope is to have a product that you can walk into and purchase, over-the-counter, from your local pharmacy,” said Wang.

Related UMass Chan news stories:
New study: MassBiologics discovers antibodies that may protect against COVID-19
Communicating science: Yang Wang discusses drug resistance in COVID-19
Drawn by mission, Mireli Fino takes the helm at MassBiologics
Gates Foundation awards MassBiologics $2M to develop treatment for enteric diarrhea
MassBiologics research into preventive shot for Lyme disease continues to move forward